Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations
- 1 March 1999
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 35, S3-S8
- https://doi.org/10.1016/s0959-8049(99)00041-6
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Metabolism, excretion and pharmacokinetics of a single dose of [ 14 C]-raltitrexed in cancer patientsCancer Chemotherapy and Pharmacology, 1998
- Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.British Journal of Cancer, 1998
- Mature results from three large controlled studies with raltitrexed ('Tomudex')British Journal of Cancer, 1998
- ‘Tomudex’ (ZD1694) : A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumoursAnnals of Oncology, 1996
- 126 Interactions and cross resistance patterns between various schedules of 5-FU and the new, folate-based thymidilate synthase inhibitor tomudex (D1694)European Journal Of Cancer, 1995
- ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancerEuropean Journal Of Cancer, 1995
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1992
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989
- Modulation of anti-metabolite effectsBiochemical Pharmacology, 1984
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984